Document is current

Article History

Received: 3 October 2021

Accepted: 11 January 2022

First Online: 18 February 2022

Competing interests

: P.T. served as advisor/consultant for AstraZeneca. P.S. reports research support (grants) to his institution from Genentech, F. Hoffmann-La Roche, OncoGenex and Novartis; reports honoraria from AstraZeneca, F. Hoffmann-La Roche, Medscape and G1 Therapeutics; reports a consulting or advisory role with AstraZeneca, Novartis, F. Hoffmann-La Roche, Merck, Boehringer Ingelheim, Bayer, Eisai, Celgene, Pfizer and Puma; and reports that his spouse has a consulting role for Genentech and F. Hoffmann-La Roche. J.C. has declared consulting role for Roche, Celgene, Cellestia, AstraZeneca, Biothera Pharmaceutical, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, MSD, GlaxoSmithKline (GSK), Leuko, Bioasis, and Clovis Oncology; honoraria from Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, MSD, and Daiichi Sankyo; research funding to the institution from Roche, Ariad Pharmaceuticals, AstraZeneca, Baxalta GMBH–Servier Affaires, Bayer healthcare, Eisai, F Hoffman-La Roche, Guardant Health, MSD, Pfizer, Piqur Therapeutics, Puma C, and Queen Mary University of London and intellectual property for MedSIR. E.A.M. served as advisor/consultant for: Bristol Myers Squib, Exact Sciences (formerly Genomic Health), Genentech/Roche, Lily and Merck. H.S.R. reports the following: Research support for clinical trials through the University of California: Pfizer, Merck, Novartis, Lilly, Roche, Odonate, Daiichi, Seattle Genetics, Macrogenics, Sermonix, Boehringer Ingelheim, Polyphor, Astra Zeneca, OBI and Immunomedics. Honoraria: Puma, Mylan, Samsung. S.M.T. has served as an advisor/consultant to Novartis, Eli Lilly, Pfizer, Merck, AstraZeneca, Eisai, Puma, Genentech, Immunomedics, Nektar, Tesaro, Daiichi Sankyo, Athenex, Bristol Meyers Squibb, and Nanostring. G.B. received honoraria for speaker, consultancy or advisory rule from Roche, Pfizer, AstraZeneca, Lilly, Novartis, Neopharm Israel, Amgen, MSD, Chugai, Sanofi, Daiichi Sankyo, EISAI, Gilead, Seagen, Exact Science, Gilead, Seagen. F.A. received research funding and served as speaker/advisor (compensated to the hospital) for Roche, AstraZeneca, Daiichi Sankyo, Pfizer, Novartis and Lilly. G.C. received honoraria for speaker, consultancy or advisory rule from AstraZeneca, Roche, Pfizer, Novartis, Seattle Genetics, Lilly, Ellipses Pharma, Foundation Medicine, Daiichi Sankyo and Samsung. The remaining authors declare no competing interests.